Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Mesenchymal stem cells require the peripheral immune system for immunomodulating effects in animal models of multiple sclerosis.
Activation of the adenosine A2A receptor exacerbates experimental autoimmune neuritis in Lewis rats in association with enhanced humoral immunity.
Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series.
High dose antigen treatment with a peptide epitope of myelin basic protein modulates T cells in multiple sclerosis patients.
Human adipose-derived mesenchymal stem cells engineered to secrete IL-10 inhibit APC function and limit CNS autoimmunity.
Targeting estrogen receptor β in microglia and T cells to treat experimental autoimmune encephalomyelitis.
Mir-155 as a multiple sclerosis-relevant regulator of myeloid cell polarization.
Developing and implementing lifestyle management programs© with people with multiple sclerosis.
Modulation of TLR3/TLR4 inflammatory signaling by the GABAB receptor agonist baclofen in glia and immune cells: relevance to therapeutic effects in multiple sclerosis.
[Symptoms and clinical manifestations in neuromyelitis optica].
Relationship between gait initiation and disability in individuals affected by multiple sclerosis.
Orthopaedic Management of Spasticity.
Pro-inflammatory pattern of IgG1 Fc glycosylation in multiple sclerosis cerebrospinal fluid.
Management of multiple sclerosis.
Impact of transcranial direct current stimulation on fatigue in multiple sclerosis.
Serum phosphorylated neurofilament-heavy chain levels in multiple sclerosis patients.
Month of birth and the incidence of multiple sclerosis in southern iran.
CRYAB-650 C>G (rs2234702) affects susceptibility to Type 1 diabetes and IAA-positivity in Swedish population.
T2-relaxometry for myelin water fraction xtraction using wald distribution and extended phase graph.
Noradrenergic regulation of glial activation: molecular mechanisms and therapeutic implications.
Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE.
Leukotrienes induce the migration of Th17 cells.
Classification algorithms with multi-modal data fusion could accurately distinguish neuromyelitis optica from multiple sclerosis.
[Assessment of the effectiveness and safety of Sativex ® in compassionate use].
Evaluation of the effects of group psychotherapy on cognitive function in patients with multiple sclerosis with cognitive dysfunction and depression.
Pages
« first
‹ previous
…
563
564
565
566
567
568
569
570
571
…
next ›
last »